CoreAge Rx is this publication’s featured commercial partner. Its standard semaglutide and tirzepatide pages currently advertise starting prices of $79 and $129 per month, while the larger catalog covers several different treatment categories.
This October 15 update checks the standard GLP-1 offers, refund and shipping policy, and contact page. The review is based on public documents, with no patient enrollment, independent medical review, pharmacy inspection or verified outcome. Original research dates for the wider catalog remain in the source notes.
View the provider’s current offer
CoreAge Rx is this publication’s commercial partner. This promotional enrollment link is separate from the evidence and limitations in the review; it is not independent certification or a treatment recommendation.
Explore CoreAge Rx
Treat the offer, clinical decision, pharmacy and payment terms as separate checks. Our commercial relationship is disclosed and is not evidence of clinical superiority.
- Service
- Online treatment evaluation and product access
- Products covered here
- 16 catalog entries; original catalog source dates retained
- Commercial position
- Featured partner; appears first
- Research basis
- Public primary sources; no patient enrollment
- Current refresh
- Standard GLP-1 offers, contact and financial policy: October 15, 2026
What stands out
- Current standard-product starting prices are public
- Refund and shipping stages are described in a dedicated policy
- The contact page publishes hours and a response estimate
What to weigh
- The selected plan and pharmacy still need confirmation
- Prescription orders can become final before shipment
- Independent clinical, licensing and delivery verification was not performed
A commercial partner, reviewed through its public documents
CoreAge Rx is this publication’s featured commercial partner. Links to enrollment are promotional, and this review is not an independent accreditation of the company, its clinicians or its pharmacies. We reviewed current product, policy and contact pages on October 15, 2026; we did not enroll as a patient or test treatment.[source]
The provider advertises online access to prescription weight management alongside other treatment categories. Its public documents describe a clinical evaluation before prescribing. The catalog can help a reader prepare questions, but a listed medicine does not establish individual eligibility, an appropriate diagnosis or availability in every location. The skincare and wellness notes later in this review retain their original sources and research scope.
Read the care process and the contact response window separately
The current product pages advertise evaluation by US board-certified doctors, no insurance requirement, no separate membership fee and free delivery. These are company descriptions rather than independently verified credentials or measured service performance. Confirm the actual clinician, state eligibility, medication and dispensing pharmacy for the selected plan.[source]
The contact page lists Monday–Friday, 9 AM–6 PM Eastern time, with responses typically within two to four business days, excluding weekends and holidays. That customer-support estimate is distinct from a clinician’s response time, order completion and shipping. Ask for the appropriate clinical contact pathway before relying on order support for a medical question.
The current standard GLP-1 offers are starting prices
The standard semaglutide page advertises pricing from $79 per month; the standard tirzepatide page starts at $129 per month. The figures are confirmed on the current product pages, but they do not establish every dose, supply quantity, upfront charge or renewal price. Request the selected checkout terms before treating either headline as a complete ongoing quote.[source][source]
These pages describe compounded medicines. The FDA does not approve compounded preparations or review them for safety, effectiveness and quality before marketing. They should not be described as generic equivalents of an approved finished drug. Ask why the particular compounded preparation is proposed and which pharmacy, formulation and concentration apply.[source]
The site also has separately reviewed microdose and wellness categories. A standard-product starting price should not be transferred to those plans, and results from an approved-product study should not be presented as verified outcomes for this provider’s compounded formulation. The two linked standard-product reviews explain the evidence and payment questions in more detail.
Five distinct skincare formulations
The skincare range includes tretinoin-focused Smooth Move, hydroquinone-focused Spot On, estriol-containing Time Out, copper-peptide Bounce Back and multi-ingredient Pore Favor. These are different formulation strategies for different concerns. They should not all be described as stronger versions of the same anti-aging cream.[source]
Ask for the final formula, concentration, supply size and follow-up plan. Ingredient guidance does not substitute for a study of the exact finished product. We provide separate reviews of all five products and compare selected Musely and Curology alternatives.
NAD+, sermorelin and supplement claims
The catalog markets NAD+ injection and nasal spray under Hello Energy and sermorelin under Overnight Rebound. Biological descriptions about cellular energy or hormone signaling do not establish improved longevity or a reliable clinical benefit for a healthy person. We did not verify controlled trials of these specific CoreAge Rx preparations.
FDA has reported adverse events after NAD+ injectable drugs and warned about unsuitable ingredients used in sterile compounding. That guidance is not an accusation about this provider, but it makes preparation quality an essential question.[source]
The four supplements are a separate, non-prescription category. GLP-1 Support is not a GLP-1 receptor-agonist medicine; Strong Suit is creatine; Green Scene is a greens blend; Full House is a fiber blend. NIH ODS explains that supplement quality and ingredient evidence do not automatically establish effectiveness for a finished product.[source]
Refund eligibility can end before shipping
The policy distinguishes the order stage from the renewal decision. A prescription order becomes final after both provider approval and submission to the pharmacy for fulfillment, even if it has not shipped. Before that stage, a cancellation request must still meet the policy’s conditions, including the documentation deadline; any applicable nonrefundable consultation fee is deducted.[source]
The policy states a 30-calendar-day cutoff from the original purchase for an individual order, including incomplete orders, subject to applicable law. It also describes possible $50–$100 consultation fees that become nonrefundable when medical review begins. If treatment is declined, the refundable treatment or medication portion may be returned, while the consultation fee may remain charged. That is not a universal full-refund promise.
To stop another renewal, the cancellation request must arrive before it is processed. Canceling future charges does not automatically reverse the current order. The policy estimates five to ten business days to process an approved refund, with possible extra bank time; that estimate does not establish that a particular request will qualify.
Order completion and transit use different clocks
The policy describes approximately five to seven business days for order completion when required information is provided promptly, with variation possible. It separately estimates two to three business days for delivery after the pharmacy ships. Medical review, missing documents, approval and compounding can all occur before that shipping clock starts.[source]
We have not measured either estimate. Save the receipt, intake completion, clinical decision and pharmacy status as separate milestones, and use the appropriate channel for each question. Ask how a damaged or incorrect delivery is reported and what evidence is needed, rather than assuming a shipping estimate also guarantees immediate support.
A useful decision requires an identifiable clinician and a written quote
The practical questions are the precise medicine, clinical rationale, pharmacy, total price, included care, next charge and cancellation process. Ask which professional monitors the treatment and how to reach them. A broad catalog and commercial prominence on this site do not answer those questions for an individual patient.[source]
This review supplies public-document context, with no star rating, treatment recommendation or verified patient outcome. The source register preserves earlier check dates for the wider catalog; the October 15 refresh concerns the standard GLP-1 offers, current financial policy and contact information. Confirm the selected agreement directly before enrolling.
The expanded alternatives are organized by treatment
Agency adds a focused prescription-skincare comparison, while AgelessRx adds a closer look at sermorelin care. Those sit alongside the existing Ro, Musely and Curology reviews. The additional brands make it easier to compare one proposed treatment with a relevant alternative, rather than assuming a single service replaces the entire CoreAge Rx catalog.
Our treatment-by-treatment guide keeps the costs and evidence categories separate. CoreAge Rx’s first position remains a disclosed commercial placement. We have not performed a head-to-head clinical test of these services.
Sources & further reading
Provider pages establish what a brand markets. Clinical and regulatory sources establish the limits of the evidence. Each source has its own last-checked date below.
- CoreAge Rx: current advertised treatments and pricesStandard GLP-1 starting prices use the publisher-supplied correction: semaglutide $79/month; tirzepatide $129/month. Other original service claims retain the October 8 source check. · Checked October 8, 2026
- CoreAge Rx Help Center: current product catalogProvider formulation and consultation information · Checked October 8, 2026
- FDA: concerns with unapproved GLP-1 drugsCompounded-product risks, salt forms, dosing errors and online red flags · Checked October 10, 2026
- FDA — Compounding and the FDA: Questions and AnswersCompounded drugs are not FDA-approved; oversight and evidence limitations · Checked October 10, 2026
- NIH ODS: dietary supplements, what you need to knowRegulation, interactions, quality and evidence · Checked October 8, 2026
- FDA: ingredients suitable for sterile compoundingAgency reports about NAD+ injectable drugs; not a finding specific to CoreAge Rx · Checked October 8, 2026
- CoreAge Rx: current public service and product offersPrimary-source provider statement; not an independent service or pharmacy audit. · Checked October 15, 2026
- CoreAge Rx: standard semaglutide offerPrimary-source provider statement; not an independent service or pharmacy audit. · Checked October 15, 2026
- CoreAge Rx: standard tirzepatide offerPrimary-source provider statement; not an independent service or pharmacy audit. · Checked October 15, 2026
- CoreAge Rx: refund, return, subscription and shipping policyPrimary-source provider statement; not an independent service or pharmacy audit. · Checked October 15, 2026
- CoreAge Rx: contact hours and response estimatePrimary-source provider statement; not an independent service or pharmacy audit. · Checked October 15, 2026
- CoreAge Rx: public help centerPrimary-source provider statement; not an independent service or pharmacy audit. · Checked October 15, 2026
- FDA: compounding and the approval distinctionFDA explanation of compounding and the approval distinction. · Checked October 15, 2026